A systematic review of randomised controlled trials on topical nasal steroids

CONCLUSIONS: BDP nasal spray is one of the most frequently prescribed INC for rhinitis and rhinosinusitis. Treatment with BDP resulted in significant and clinically meaningful improvements in nasal symptoms associated with AR and CRS. BDP is well tolerated, and the safety profile is similar to that of placebo in most patients. These results, in conjunction with the significant benefit reported in subjects with CRS and AR, provide convincing evidence of the overall effectiveness of BDP for the treatment of the full spectrum of sinonasal disease.PMID:38651550 | DOI:10.14639/0392-100X-N2745
Source: Acta Otorhinolaryngologica Italica - Category: ENT & OMF Authors: Source Type: research